Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Gains from Investment Securities (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Gains from Investment Securities for 3 consecutive years, with $315000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities fell 69.71% to $315000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $368000.0 through Dec 2025, up 362.86% year-over-year, with the annual reading at $1.9 million for FY2025, 96.47% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was $315000.0 at Nuvation Bio, down from $1.8 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $32.9 million in Q3 2023, with the low at -$1.1 million in Q2 2024.
  • Average Gains from Investment Securities over 3 years is $3.2 million, with a median of $315000.0 recorded in 2025.
  • The sharpest move saw Gains from Investment Securities tumbled 528.3% in 2024, then soared 441.9% in 2025.
  • Over 3 years, Gains from Investment Securities stood at -$597000.0 in 2023, then surged by 274.2% to $1.0 million in 2024, then tumbled by 69.71% to $315000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $315000.0, $1.8 million, and -$454000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.